Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

doi:10.1200/PO-25-00769

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology - 1 Jun 2026

Kummar Shivaani, Song Zihe, Reiss Kim A, Ford James M, Chen Li, Rolig Annah S, Zwiebel James A, Gore Steven D, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Gross Jacob, Brunnquell Donna, Jackson Latifa F, Williams P Mickey, Hamilton Stanley R, Takebe Naoko, Brufsky Adam, Tricoli James V, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith T

Abstract excerpt

PURPOSE: Inhibition of WEE1, a tyrosine kinase responsible for G2 arrest, results in premature mitotic entry and double-strand DNA breaks. Adavosertib is a selective, ATP-competitive, and small-molecule WEE1 kinase inhibitor. In an adavosertib single-agent, Phase I trial, partial responses (PRs) were observed in patients with solid tumors carrying pathogenic variants (PVs) in BRCA1/2. In this trial, we further...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 42308463
DOI: 10.1200/PO-25-00769
PMCID: PMC13335521

Genes

BRCA1
WEE1
BRCA2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.PMID 42308463Read ↗

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.Semantic proximity Read ↗

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).Semantic proximity Read ↗

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.Semantic proximity Read ↗

Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.Semantic proximity Read ↗

Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 InhibitionSemantic proximity Read ↗

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)Semantic proximity Read ↗

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic CancersSemantic proximity Read ↗

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.Semantic proximity Read ↗

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Semantic proximity Read ↗

Phase 2 Study of TAS-117 in Advanced Solid Tumors Harboring Phosphatidylinositol 3-Kinase/v-akt Murine Thymoma Viral Oncogene Homolog Gene AberrationsSemantic proximity Read ↗

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.Semantic proximity Read ↗

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.